TYMS is highly expressed in patients with colorectal cancer and non-small cell lung cancer, and patients with lower TYMS mRNA levels have higher survival rates than those with higher expression (Sun et al., 2015; Jiang et al., 2019). This evidence concerns the gene TYMS and colorectal cancer.